Voltage-dependent L-type calcium channel (LTCC)

The Voltage-dependent L-type calcium channel is a high-voltage-activated ion channel complex found in most excitable cells, including muscle (cardiac, skeletal, and smooth), neurons, endocrine cells, and others. It is responsible for mediating the influx of calcium ions into cells upon membrane depolarization, enabling key processes such as muscle contraction (excitation-contraction coupling), hormone and neurotransmitter release, gene expression, and cellular signaling pathways. The channel is composed of multiple subunits, with the α1 (Cav1.x) subunit forming the core pore and determining its pharmacological properties. There are several isoforms (e.g., Cav1.1 in skeletal muscle, Cav1.2 in cardiac and smooth muscle, Cav1.3 in neurons), each with specific tissue distributions and physiological roles. Due to its central role in cellular excitability and signaling, it is therapeutically targeted in various conditions, most prominently cardiovascular (hypertension, arrhythmia) and neurological (neurodegenerative, epileptic, and psychiatric) disorders. The principal drugs targeting LTCCs are calcium channel blockers, which bind to specific sites and inhibit calcium ion entry, providing clinical efficacy in lowering blood pressure, reducing cardiac workload, and modulating neuronal excitability.

Other names

L-type calcium channelL-type VDCCLTCCCav1 channelCav1.2Cav1.3Voltage-gated L-type calcium channel

Channel blockade: Competitive or allosteric inhibition of calcium influx by binding to specific sites on the channel (dihydropyridines, phenylalkylamines, benzothiazepines); Modulation of voltage sensitivity or gating (some investigational agents)